Viewing Study NCT00421915



Ignite Creation Date: 2024-05-05 @ 5:16 PM
Last Modification Date: 2024-10-26 @ 9:30 AM
Study NCT ID: NCT00421915
Status: COMPLETED
Last Update Posted: 2007-01-15
First Post: 2007-01-08

Brief Title: Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Organization: Wyeth is now a wholly owned subsidiary of Pfizer

Study Overview

Official Title: Multicenter Double-Blind Parallel Placebo-Controlled Randomised Phase 3 Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis 12-Week Final Data
Status: COMPLETED
Status Verified Date: 2007-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of the study was to compare the efficacy of etanercept 25 mg twice weekly with that of placebo based on the percentage of patients who achieve the Assessment in Ankylosing Spondylitis ASAS response criteria ASAS 20 at week 12
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None